Sick leave for follow-up control in thyroid cancer patients: Comparison between stimulation with Thyrogen and thyroid hormone withdrawal

European Journal of Endocrinology

Volumn 156, Issue 5, 2007, Pages 531-538

  Borget, I ^a   Corone, C ^b   Nocaudie, M ^c   Allyn, M ^d   Iacobelli, S ^a   Schlumberger, M ^a   De Pouvourville, G ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b CENTRE RENÉ HUGUENIN   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d GENZYME CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RADIOACTIVE IODINE; RECOMBINANT THYROTROPIN;

ABSENTEEISM; ADULT; AGED; ARTICLE; CANCER CONTROL; CONTROLLED STUDY; COST OF ILLNESS; FEMALE; FOLLOW UP; HORMONAL REGULATION; HUMAN; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MALE; MEDICAL LEAVE; PRIORITY JOURNAL; QUESTIONNAIRE; RADIOFREQUENCY ABLATION; THYROID CARCINOMA; THYROIDECTOMY; TREATMENT WITHDRAWAL; WORK;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, PAPILLARY, FOLLICULAR; COST OF ILLNESS; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; SICK LEAVE; THYROID NEOPLASMS; THYROTROPIN;

EID: 34248998448     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/EJE-06-0724     Document Type: Article

References (20)

1. Boyle P & Ferlay J. Cancer incidence and mortality in Europe, 2004. Annals of Oncology 2005 16 481-488.
2. Mazzaferri EL. An overview of the management of papillary and follicular thyroid carcinoma. Thyroid 1999 9 421-427.
3. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW & Wiersinga W. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. European Journal of Endocrinology 2006 154 787-803.
4. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, Mciver B, Sherman SI & Tuttle RM. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006 16 109-142.
5. Schlumberger M, Pacini F, Wiersinga WM, Toft A, Smit JW, Sanchez Franco F, Lind P, Limbert E, Jarzab B, Jamar F, Duntas L, Cohen O & Berg G. Follow-up and management of differentiated thyroid carcinoma: a European perspective in clinical practice. European Journal of Endocrinology 2004 151 539-548.
6. Eustatia-Rutten CF, Smit JW, Romijn JA, Van Der Kleij-Corssmit EP, Pereira a M, Stokkel MP & Kievit J. Diagnostic value of serum thyroglobulin. Clinical Endocrinology 2004 61 61-74.
7. Haugen BR, Pacini F, Reiners C, Schlumberger M, Ladenson PW, Sherman SI, Cooper DS, Graham KE, Braverman LE, Skarulis MC, Davies TF, Degroot LJ, Mazzaferri EL, Daniels GH, Ross DS, Luster M, Samuels MH, Becker DV, Maxon HR III, Cavalieri RR, Spencer CA, Mcellin K, Weintraub BD & Ridgway EC. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. Journal of Clinical Endocrinology and Metabolism 1999 84 3877-3885.
8. Ladenson PW, Braverman LE, Mazzaferri EL, Brucker-Davis F, Cooper DS, Garber JR, Wondisford FE, Davies TF, Degroot LJ, Daniels GH, Ross DS & Weintraub BD. Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. New England Journal of Medicine 1997 337 888-896.
9. Dow KH, Ferrell BR & Anello C. Balancing demands of cancer surveillance among survivors of thyroid cancer. Cancer Practice 1997 5 289-295.
10. Davids T, Witterick IJ, Eski S, Walfish PG & Freeman JL. Three-week thyroxine withdrawal: a thyroid-specific quality of life study. Laryngoscope 2006 116 250-253.
11. Dow KH, Ferrell BR & Anello C. Quality-of-life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy. Thyroid 1997 7 613-619.
12. Luster M, Felbinger R, Luster M, Felbinger R, Dietlein M & Reiners C. Thyroid hormone withdrawal in patients with differentiated thyroid carcinoma: a one hundred thirty-patient pilot survey on consequences of hypothyroidism and a pharmacoeconomic comparison to recombinant thyrotropin administration. Thyroid 2005 15 1147-1155.
13. Schroeder PR, Haugen BR, Pacini F, Reiners C, Schlumberger M, Sherman SI, Cooper DS, Schuff KG, Braverman LE, Skarulis MC, Davies TF, Mazzaferri EL, Daniels GH, Ross DS, Luster M, Samuels MH, Weintraub BD, Ridgway EC & Ladenson PW. A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal. Journal of Clinical Endocrinology and Metabolism 2006 91 878-884.
14. Nijhuis TF, Van Weperen W & De Klerk JMH. Costs associated with the withdrawal of thyroid hormone suppression therapy during the follow-up treatment of well-differenciated thyroid cancer. Tijdschrift voor Nucleaire Genneskunde 1999 21 98-100.
15. Colonna M, Grosclaude P, Remontet L, Schvartz C, Mace-Lesech J, Velten M, Guizard A, Tretarre B, Buemi aV, Arveux P & Esteve J. Incidence of thyroid cancer in adults recorded by French cancer registries (1978-1997). European Journal of Cancer 2002 38 1762-1768.
16. Mernagh P, Campbell S, Dietlein M, Luster M, Mazzaferri E & Weston aR. Cost-effectiveness of using recombinant human TSH prior to radioiodine ablation for thyroid cancer, compared with treating patients in a hypothyroid state: the German perspective. European Journal of Endocrinology 2006 155 405-414.
17. Koopmanschap MA, Rutten FF, Van Ineveld BM & Van Roijen L. The friction cost method for measuring indirect costs of disease. Journal of Health Economics 1995 14 171-189.
18. Hodgson TA. Costs of illness in cost-effectiveness analysis. A review of the methodology. Pharmacoeconomics 1994 6 536-552.
19. Liljas B. How to calculate indirect costs in economic evaluations. Pharmacoeconomics 1998 13 1-7.
20. Brouwer WB & Koopmanschap MA. The friction-cost method: replacement for nothing and leisure for free? Pharmacoeconomics 2005 23 105-111.